Frontlight ResearchEarly access
Not yet taking people in AustriaPhase 3
Cangrelor, a platelet-blocking drug, in children with congenital heart disease having vascular procedures
Tests the safety of cangrelor in children with congenital heart disease.
Key facts
- Who runs it
- Chiesi Farmaceutici S.p.A.
- Where
- Graz and Vienna, AustriaSee the 2 sitesAlso in 4 other countries, 7 sites
- Trial code
- Registry title
- Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 60 people, planned
- Started
- 23 Jun 2026
- Expected to end
- 21 Jan 2028
- Type of study
- Interventional
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with congenital heart disease (a heart problem present from birth). They must be due to have a heart or blood vessel procedure done through a thin tube put into a blood vessel.
- Age
- From birth to less than 18 years
- Sex
- Boys and girls
- Disease stage
- Congenital heart disease, for example patent ductus arteriosus, coarctation of aorta, atrial septal defect, ventricular septal defects or valvular stenosis. The child is expected to have a diagnostic and/or treatment procedure through a blood vessel.
- Biomarker or test result
- Platelet count between 150,000 and 450,000 cells/µL at screening.
Main reasons for not taking part
- Babies with a corrected age of <37 weeks at screening
- Past bleeding in the brain, a cerebral arteriovenous malformation (tangled blood vessels in the brain), or past bleeding that caused nerve or brain damage
- Bleeding from the gut or the urinary or genital tract within the last 2 weeks, not counting normal periods
- Platelet count less than 150,000 cells/µL or higher than 450,000 cells/µL
- Known allergy or sensitivity to Cangrelor or any part of it
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Males and females aged from birth to less than 18 years
- Diagnosis of CHD, including, but not limited to, patent ductus arteriosus, coarctation of aorta, atrial septal defect, ventricular septal defects, valvular stenosis
- Expected to undergo a diagnostic and/or therapeutic percutaneous vascular procedure
- Female subjects fulfilling one of the following criteria: • Women of non-childbearing potential (WONCBP), defined as physiologically incapable of becoming pregnant; • Women of childbearing potential (WOCBP) fulfilling one of the following criteria: o Sexually active: they and/or their partner must be willing to use a highly effective birth control method from the signature of the informed consent and until the end of the follow-up period (Day 4/discharge) o Non-sexually active (contraception is not required in this case)
- Male subjects fulfilling one of the following criteria: • Non-fertile male subjects (contraception is not required in this case); • Fertile male subjects without a female partner (contraception is not required in this case); • Fertile male subjects with any WOCBP partner: they must be willing to use male condom from the signature of the informed consent and until the end of the follow-up period (Day 4/discharge); • Fertile male subjects with WONCBP partner (contraception is not required in this case)
Who cannot take part
- History of intracerebral bleeding or cerebral arteriovenous malformation; or evidence of any prior bleeding with neurological deficit
- Gastrointestinal or genitourinary bleeding within the last 2 weeks prior to screening, excluding normal menstrual cycles
- Known allergy to Cangrelor or known sensitivity to any component of Cangrelor
- Platelet count less than 150,000 cells/µL or higher than 450,000 cells/µL at screening
- Corrected age of <37 weeks at screening
Where in Austria
Also in 4 other countries, 7 sites
- Medical University of GrazGraz, AustriaNot yet recruiting
- Medical University of ViennaVienna, AustriaNot yet recruiting
About the trial
What the trial wants to find out
To evaluate the safety profile of the recommended dosing regimen of Cangrelor in the paediatric population.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease
- Plain-language title
- Cangrelor, a platelet-blocking drug, in children with congenital heart disease having vascular proceduresGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 November 2026